Source: International Congress 2018 – CC2 Broad spectrum of chronic thromboembolic pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Mayer (Bad Nauheim, Germany). Combining therapeutical options in CTEPH. International Congress 2018 – CC2 Broad spectrum of chronic thromboembolic pulmonary hypertension

Member's Comments

No comment yet.

Related content which might interest you: Current strategies for managing CTEPH Source: Virtual Congress 2021 – Non-pulmonary arterial hypertension pulmonary hypertension Year: 2021 Advances in the therapeutical management of IPF Source: Annual Congress 2012 - MS3 Update in idiopatic pulmonary fibrosis Year: 2012 Improved identification of thrombolysis candidates amongst intermediate-risk pulmonary embolism patients: implications for future trials Source: Eur Respir J, 51 (1) 1701775; 10.1183/13993003.01775-2017 Year: 2018 Treatment of CTEPH and anticoagulation of choice Source: ERS Course 2019 - Masterclass in pulmonary embolism Year: 2019 The use of new anticoagulants in CTEPH Source: International Congress 2017 – PAH and CTEPH Year: 2017 Pharmacological options for the treatment of COPD: present and future Source: Annual Congress 2007 - PG6 - COPD: comprehensive clinical assessment and pharmacological and nonpharmacological therapy Year: 2007 Different treatment modalities in chronic thromboembolic pulmonary hypertension: how to combine them? Source: International Congress 2017 – Open questions in pulmonary vascular diseases Year: 2017 Treatment of COPD: from pharmacological to instrumental therapies Source: Eur Respir Rev 2009; 19: 7-23 Year: 2010 Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights Source: Eur Respir J 2015; 46: 414-421 Year: 2015 Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches Source: Eur Respir J 2006; 28: 463-465 Year: 2006 A pragmatic guide to choosing biologic therapies in severe asthma Source: Breathe, 17 (4) 210144; 10.1183/20734735.0144-2021 Year: 2021 Long-term riociguat treatment towards implementing a targeted treatment strategy in patients with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials Source: Eur Respir J 2015; 46: 243-249 Year: 2015 Current approaches to the prevention of tuberculosis in patients receiving immunosuppressants Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021 Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach Source: Eur Respir J 2015; 45: 1142-1149 Year: 2015